



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 9989)**

**ANNOUNCEMENT**

**PROPOSED ISSUANCE OF CORPORATE BONDS  
AND  
CHANGE IN USE OF PROCEEDS**

**PROPOSED ISSUANCE OF CORPORATE BONDS**

On 30<sup>th</sup> March 2022, the Board (the "Board") of the Company (the "Company") (the "Proposed Issuance" of Corporate Bonds) (the "PRC") (the "EGM")

**1. ISSUE SIZE**

The Company has issued B1,000,000,000 (RMB1,000,000,000)

**2. TARGET SUBSCRIBERS**

The Board of Directors of the Company has approved the following:

**3. TERM**

The Board of Directors of the Company has approved the following term (to be inserted in the prospectus):

**4. USE OF PROCEEDS**

The Board of Directors of the Company has approved the following use of proceeds (Proceeds) to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following use of proceeds (Proceeds) to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following use of proceeds (Proceeds) to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following use of proceeds (Proceeds) to be inserted in the prospectus:

**5. INTEREST RATE**

The Board of Directors of the Company has approved the following interest rate to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following interest rate to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following interest rate to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following interest rate to be inserted in the prospectus:

**6. VALIDITY OF THE RESOLUTION(S)**

The Board of Directors of the Company has approved the following resolution(s) to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following resolution(s) to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following resolution(s) to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following resolution(s) to be inserted in the prospectus:

The Board of Directors of the Company has approved the following resolution(s) to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following resolution(s) to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following resolution(s) to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following resolution(s) to be inserted in the prospectus:

**Reasons and benefits of the Proposed Issuance**

The Board of Directors of the Company has approved the following reasons and benefits of the proposed issuance to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following reasons and benefits of the proposed issuance to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following reasons and benefits of the proposed issuance to be inserted in the prospectus:   
The Board of Directors of the Company has approved the following reasons and benefits of the proposed issuance to be inserted in the prospectus:

# PROPOSED CHANGE IN USE OF PROCEEDS

## Use of Proceeds

2020 (	24	2020 (
<b>Prospectus</b> )		B
( <b>Net Proceeds</b> )	B3,538.4	
2020 ( <b>Global Offering</b> )		
2022 ( <b>Interim Report</b> )		30
2022		30

A	30%	B1,061.5
	30%	B1,061.5
		20%
		B707.7
		20%
		B707.7

A		B1,115.2
	30	2022
		B2,423.2

## Proposed Change in Use of Proceeds

本公司此次發行人民幣定向增發融資總額為人民幣3,538.4百萬元，扣除發行費用後，淨募集資金為人民幣3,538.4百萬元。本公司將根據本招股說明書中披露的用途使用該筆淨募集資金。B. 招股說明書中披露的用途與招股說明書中披露的用途相比，擬議用途的變化如下：

(Proposed Change in Use of Proceeds)

Business objectives	Original planned use of the Net Proceeds as disclosed in the Prospects (RMB million)	Utilised as at the date of this announcement (RMB million)	Remaining proceeds as at the date of this announcement (RMB million)	Revised allocation of unutilised Net Proceeds (RMB million)	Expected date of full utilisation of the unutilised Net Proceeds
(1) 用於支付發行費用	1,061.5 (30% of the net proceeds)	1,034.4	27.1	-	-
(2) 用於補充公司流動資金	1,061.5 (30% of the net proceeds)	-	1,061.5	636.9	24 months
(3) 用於償還公司債務	707.7 (20% of the net proceeds)	-	707.7	451.8	24 months
(4) 用於收購公司資產	707.7 (20% of the net proceeds)	80.8	626.9	376.2	24 months
(5) 用於其他用途	-	-	-	958.3	24 months
<b>Total:</b>	<b>3,538.4</b>	<b>1,115.2</b>	<b>2,423.2</b>	<b>2,423.2</b>	

## Reasons for and benefits of the Proposed Change in Use of Proceeds

The proposed change in use of proceeds is a result of the COVID-19 pandemic. The company has experienced a significant decline in revenue and has incurred substantial losses. The company is currently in a state of financial distress and is unable to meet its obligations. The proposed change in use of proceeds is necessary to ensure the company's survival and to allow it to continue its operations. The company is seeking to raise additional capital to cover its operating expenses and to pay its debts. The proposed change in use of proceeds is a necessary step to ensure the company's financial stability and to allow it to continue its operations.

The proposed change in use of proceeds is a result of the COVID-19 pandemic. The company has experienced a significant decline in revenue and has incurred substantial losses. The company is currently in a state of financial distress and is unable to meet its obligations. The proposed change in use of proceeds is necessary to ensure the company's survival and to allow it to continue its operations. The company is seeking to raise additional capital to cover its operating expenses and to pay its debts. The proposed change in use of proceeds is a necessary step to ensure the company's financial stability and to allow it to continue its operations.

B. ...  
B. ...  
24 A. ...  
B376.2

2021 2022  
2022 31

A

A

T B

B B  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

30 2022

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan and Mr. Shan Yu; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.*

*\* for identification purposes only*